Temozolomide in patients with high grade gliomas

Oncology

Volumn 59, Issue 3, 2000, Pages 181-186

  Brandes, Alba Ariela ^a   Pasetto, Lara Maria ^a   Vastola, Francesca ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Brain tumors; Chemotherapy; Temozolomide

Indexed keywords

CARMUSTINE; CISPLATIN; PROCARBAZINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLIOMA; HUMAN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 0033759128     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012158     Document Type: Review

References (48)

1. Cancer statistics
2. The role of chemotherapy in recurrent malignant gliomas: An overview
3. Medical treatment of high grade malignant glioma in adults: An overview
4. Chemotherapy for adults with malignant glioma
5. From triazines to temozolomide
6. Current development of temozolomide
7. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
8. 3H)-one (temozolomide) and structural comparisons with related drugs mitozolomide and DTIC
9. Investigation of human in vivo tissue and tumor pharmacokinetics and mechanism of action of temozolomide
10. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide
11. 6-methylguanine-DNA methyltransferase
12. Potentiation of temozolomide cytotoxicity by an inhibitor of alkylguanine-DNA-alkyltransferase
13. 6-alkylguanine-DNA-alkyltransferase deficient leukemia cell lines
14. Chemical xenogenization (cx) of cancer cells by triazene compounds: Studies with leukemia and melanoma cells
15. 6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines
16. 6-methylguanine-DNA-methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin
17. Mismatch repair mutator phenotype confers resistance to temozolomide in human colon cancer cell lines
18. (ADP-ribose) participates in DNA excision repair
19. 6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
20. Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
21. 3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine
22. Activity of temozolomide against human tumor colony forming units
23. Activity of temozolomide in treatment of central nervous system tumor xenografts
24. Responses of human melanoma, ovarian and colon tumor xenograft in the nude mice to oral temozolomide
25. In vitro activation of dacarbazine (DTIC) for a human tumor coloning system
26. Phase I trial of temozolomide
27. The kinetic behavior of temozolomide in man
28. 14C-temozolomide in patients with advanced cancer
29. Effect on food on the oral bioavailability of temozolomide, a new chemotherapeutic agent
30. Effect of ranitidine on the pharmacokinetics (PK) of temozolomide
31. A phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer
32. Phase I clinical pharmacokinetic study of temozolomide in advanced cancer patients stratified by extent of prior therapy
33. Phase I study of temozolomide in pediatric patients with advanced cancer
34. 3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3
35. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer
36. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
37. A phase I study of temozolomide combined with cisplatin (CDDP) in patient with advanced cancer
38. Phase I and pharmacokinetic (PK) trial sequences of BCNU and temozolomide (TMZ) in patients with solid neoplasm
39. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors
40. The Charing Cross Hospital experience with temozolomide in patients with gliomas
41. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
42. Chemotherapy in the treatment of recurrent glioblastoma multiforme: Ifosfamide versus temozolomide
43. Randomized trial of temodal (TEM) vs procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse
44. Multicenter phase-II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
45. Temozolomide (TMZ) in high grade gliomas (HGG) at second relapse: A phase II study
46. 6-methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma
47. Systemic therapy of metastatic melanoma
48. Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group